Praxis Medical Insights

Est. 2024 • Clinical Guidelines Distilled

Made possible by volunteer editors from the University of Calgary & University of Alberta

Last Updated: 12/30/2025

Ceftazidime-Avibactam Dosing Considerations

Standard Dosing and Renal Impairment

  • The standard dose of 2.5 g IV every 8 hours over 2-3 hours is recommended for patients with creatinine clearance (CrCl) >50 mL/min, according to the Infectious Diseases Society of America guidelines 1, 2, 3
  • This dosing applies across all approved indications, including complicated urinary tract infections, complicated intra-abdominal infections, and CRE bloodstream infections, as recommended by the American College of Clinical Pharmacy 1, 2

Dose Adjustments for Renal Impairment

  • The FDA recommends dose reduction for patients with moderate to severe renal impairment, with specific adjusted doses following FDA labeling recommendations, to prevent drug accumulation and neurotoxicity 4
  • The European Medicines Agency guidelines suggest that ceftazidime-avibactam should be administered after hemodialysis, as approximately 55% of avibactam is removed during a 4-hour dialysis session, to maintain therapeutic levels 1, 3

Key Safety Considerations

  • The American College of Clinical Pharmacy recommends monitoring for neurotoxicity, including seizures, encephalopathy, and confusion, particularly in patients with renal impairment, due to the risk of beta-lactam accumulation 4
  • The Infectious Diseases Society of America guidelines suggest that ceftazidime has lower pro-convulsive activity than some other beta-lactams, but vigilance remains essential to prevent neurotoxicity 4

Extended Infusion Duration Improves Survival in KPC‑Producing Infections

Clinical Outcome Evidence

  • Extending the infusion of a 2.5 g dose of ceftazidime‑avibactam to 3 hours (instead of the standard 2 hours) was associated with higher 30‑day survival in patients infected with KPC‑producing organisms【5】. Evidence level: observational cohort study (2022).